Trulieve: Analysts Expect US$221 Million In Q3 Revenues

Trulieve (CSE: TRUL) announced that they will be reporting their third quarter financials before the market opens on November 15th.

Analysts have a consensus C$84.53 12-month price target on the company, via a total of 17 analysts, representing an upside of 118%. 5 analysts have strong buy ratings, and the other 12 have buy ratings on the company. The street high comes from Stifel-GMP with an C$135 price target, and the lowest target is a C$54 price target.

14 analysts have revenue estimates for the third quarter. The mean between all 14 is US$221.01 million; this number has been revised slightly down from US$228.46 million at the start of May. The street high is US$2224.40 million while the lowest sits at US$216.15 million.

10 analysts have estimates for what this quarter’s gross profit margin will be. They expect the profit margin to come in at 65.90%, with this number being revised down from 70.13% at the start of May. Street high is 68% estimate and the lowest sits at 63.50%.

Onto EBITDA estimates, there are currently 14 analysts who have third-quarter EBITDA estimates. The mean is currently US$89.35 million, with this number being revised down from US$99.88 million at the start of May. Street high sits at US$97 million EBITDA and the lowest being a US$781.2 million estimate.


Information for this briefing was found via Sedar and Refinitiv. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

First Majestic Q1 Earnings: A Bang Up Quarter

Copper’s Structural Shortage May Be Here to Stay | Colin Joudrie – Selkirk Copper

Why Barrick’s “Strong” Quarter Wasn’t So Strong | Q1 2026 Earnings

Recommended

Questcorp Wraps Expanded Drone Survey at La Union as Summer Drilling Approaches

Altamira Gold Extends Maria Bonita Footprint with 110 Metre Step-Out

Related News

Medipharm Labs: Canaccord Drops Target To Just $0.10

On May 16, Medipharm Labs (TSX: LABS) reported its first quarter financial results. The company...

Tuesday, May 24, 2022, 11:37:00 AM

Organigram: Consensus Price Target Falls To $3.55

On November 23rd, Organigram Holdings (TSX: OGI) announced its fourth quarter fiscal 2021 results. The...

Sunday, November 28, 2021, 01:18:00 PM

SLANG Worldwide: Canaccord Raises FY2020 Revenue Estimates Following Q2 Earnings

SLANG Worldwide (CSE: SLNG) announced their second-quarter financials yesterday, with revenue coming in at $4.6...

Friday, August 28, 2020, 01:48:00 PM

BMO: Nuvei Expected To Record Net Revenues Of $97 Million In Q3 2020

This morning, BMO Capital Markets released a note to investors updating their forecast and model...

Wednesday, November 4, 2020, 11:26:38 AM

Columbia Care Sees Consensus Price Target Rise To $14.70

On August 12, Columbia Care Inc. (CSE: CCHW) reported its second-quarter financial results, wherein the...

Wednesday, August 18, 2021, 10:09:00 AM